KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Cash & Current Investments: 2009-2024

Historic Cash & Current Investments for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $9.0 billion.

  • Regeneron Pharmaceuticals' Cash & Current Investments fell 13.81% to $8.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $33.3 billion, marking a year-over-year decrease of 18.78%. This contributed to the annual value of $9.0 billion for FY2024, which is 16.90% down from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported Cash & Current Investments of $9.0 billion as of FY2024, which was down 16.90% from $10.8 billion recorded in FY2023.
  • In the past 5 years, Regeneron Pharmaceuticals' Cash & Current Investments ranged from a high of $10.8 billion in FY2023 and a low of $3.6 billion during FY2020.
  • For the 3-year period, Regeneron Pharmaceuticals' Cash & Current Investments averaged around $9.2 billion, with its median value being $9.0 billion (2024).
  • As far as peak fluctuations go, Regeneron Pharmaceuticals' Cash & Current Investments soared by 58.76% in 2021, and later decreased by 16.90% in 2024.
  • Yearly analysis of 5 years shows Regeneron Pharmaceuticals' Cash & Current Investments stood at $3.6 billion in 2020, then surged by 58.76% to $5.7 billion in 2021, then spiked by 35.96% to $7.7 billion in 2022, then soared by 40.07% to $10.8 billion in 2023, then decreased by 16.90% to $9.0 billion in 2024.